TLR7 and systemic lupus erythematosus: Furthermore, TLR7 and TLR9 responses were reversely or differentially regulated on pDCs in SLE, implying that for the pharmaceutical application, TLR7, but not TLR9, should be targeted when targeted therapies are developed in patients with SLE.